Drug intelligence / Profile preview

NTM-1634

Development stage: Phase 1
Lead developer: XOMA
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**NTM-1634** is an investigational, fixed-dose oligoclonal botulinum antitoxin composed of an equimolar mixture of four fully human IgG1 monoclonal antibodies. The antibodies bind distinct, nonoverlapping epitopes on botulinum neurotoxin serotypes C and D and their C/D and D/C mosaic toxins, neutralizing the toxins and promoting their rapid clearance. It was developed as a medical countermeasure for botulism and completed a first-in-human Phase 1 intravenous dose-escalation study in healthy adults, where single doses were reported to be well tolerated. ([journals.asm.org](https://journals.asm.org/doi/10.1128/aac.01270-19))

Other names: NTM 1634NTM1634NTM-1634

Targets

BoNT/D (Botulinum neurotoxin type D)BoNT/C (Botulinum neurotoxin type C)

Beyond the preview

Go deeper on NTM-1634.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTM-1634.

Explore the full profile